The European Commission has recently published a comprehensive package of regulatory reforms for the pharmaceutical sector in the European Union (EU), setting out a legislative action plan and strategic vision that seeks to balance greater patient access, improved regulatory efficiency, and the need to boost the Life Sciences sector’s global competitiveness. Join us, Tim Wilsdon and Anthony Barron, as we explore some of the key components of the new Pharmaceutical Strategy for Europe and set out some of the policy initiatives stemming from the strategy.
Paving the way for expanded GLP-1 coverage
GLP-1 agonists were originally approved to treat Type 2 Diabetes (T2D) – but their most recent incarnations, which consist of both next generation GLP-1s and...